Bolin RR (1960) Psychiatric manifestations of artane toxicity. J Nerv Ment Dis, 131:256-259.
Buhrich N, Weller A, Kevans P (2000) Misuse of anticholinegic drugs by people with serious mental illness. Psychiatry Serv, 51:928-929.
Corcos J, Gajewski J, Heritz D ve ark. (2006) Canadian Urological Association guidelines on urinary incontinence. Can J Urol, 13(3):3127-3138.
Gjerden P, Bramness JG, Slordal L (2008) The use and potential abuse of anticholinergic antiparkinson drugs in Norway: apharmacoepidemiological study. Br J Clin Pharmacol, 67:228-233.
Guloksuz S, Eren K, Gurol DT (2010) A case of oxybutinin dependency. Gen Hosp Psychiatry, 32(4):e5-6. Ogino S, Miyamoto S, Tenjin T ve ark. (2010) Effects of long term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropharmacol Biol Psychiatry, 15;35(1):78-83.
Pullen GP, Best NR, Maguire J (1984) Anticholinergic drug abuse: a common problem? British Medical Journal, 289:612-613.
Sadock BJ, Sadock VA (2007) Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Sekizinci Baskı, cilt 2, (Çeviri ed.: H Aydın, A Bozkurt) Güneş Kitabevi, Ankara. s.1158-1160.
Sağlık Bakanlığı (1986) Psikotrop ilaç reçeteleri hakkında genelge. (Tarih: 2.1.1986 ve Sayı: 09/2677). Yuksek MS, Erdem AF, Atalay C ve ark. (2003) Acupressure versus oxybutinin in the treatment of enuresis. The Journal of International Medical Research, 31:552-556.